ALFA Finder| Management target | Revenue FY30 |
|---|
| Revenue growth | 16.6% YoY in FY26. |
|---|---|
| Margins | EBITDA margin expansion from 18.5% to 19.4% over FY24-FY26. |
| Demand visibility | Strong domestic chronic demand and Europe/Canada pipeline. |
| Management confidence | High; citing 'stronger returns' and 'diversified growth platform'. |
Growth
FY26 revenue grew 16.6% YoY; PAT surged 33% YoY. EBITDA margins improved to 19.4% (+90 bps).
Outlook
Targets FY26-FY30 growth via obesity/oncology assets and R&D platforms like Biologics and ADCs.
Risks
Regulatory changes, supply chain challenges, and currency fluctuations in international markets.
Last quarter's promises, checked
Delivered
- Revenue growth low-to-mid-teens → Delivered 22.8% (= BEAT)
- Domestic growth return to double-digits → Delivered 10.2% (= BEAT)
- EBITDA margin expansion 70-100 bps → Delivered 19.7%, up 50 bps YoY but 120 bps vs FY24 (= BEAT)
Partly delivered
- Gross margin target 60% → Delivered 58.4% due to product mix (= PARTIAL)
Investor Presentation filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,361.70
- Market cap
- ₹44,804 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 41.0×Sector 43.7×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.
- Call
- Guides 20% growth
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.
Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹325.1 Cr · +29.3% YoY
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.